Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00SYV
|
|||
| Former ID |
DIB005722
|
|||
| Drug Name |
GSK2618960
|
|||
| Indication | Multiple sclerosis [ICD-11: 8A40; ICD-9: 340] | Phase 1 | [1] | |
| Sjogren syndrome [ICD-11: 4A43.20; ICD-10: M35, M35.0] | Phase 1 | [2] | ||
| Company |
Glaxosmithkline
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin-7 (IL7) | Target Info | Modulator | [3] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| PI3K-Akt signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| NetPath Pathway | TNFalpha Signaling Pathway | |||
| Panther Pathway | Interleukin signaling pathway | |||
| Reactome | Interleukin-7 signaling | |||
| WikiPathways | Cytokines and Inflammatory Response | |||
| Interleukin-7 signaling | ||||
| IL-7 Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01808482) A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | ClinicalTrials.gov (NCT02293161) Single Ascending Doses Study of Anti- Interleukin-7 Receptor alpha Monoclonal Antibody (GSK2618960) in Healthy Volunteers. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.